Optimal management of luminal breast cancer: how much endocrine therapy is long enough?

Research output: Contribution to journalReview article

Abstract

Patients with early estrogen receptor-positive breast cancer are at continuous risk of relapse even after more than 10 years of follow up. Currently, no biomarker that identifies patients for early versus late recurrence, or one that selects patients or tumors for longer versus shorter durations of endocrine therapy (ET) is available and a crucial question is how to properly select patients who could be spared extended ET or those who require it. In the last 20 years more than 40,000 women were enrolled in randomized trials to answer the question of optimal duration of ET. According to the results of these studies extended adjuvant ET is more effective than standard 5 years of adjuvant ET. Extended ET in patients who remain premenopausal after 5 years of adjuvant tamoxifen is still tamoxifen for another 5 years. Extended ET with aromatase inhibitors (AIs) should be offered to postmenopausal women with substantial residual risk of relapse after completing 5 years of tamoxifen therapy. Extension of AI treatment to 10 years resulted in significantly better 5-year disease-free survival including disease recurrence local/distant or the occurrence of contralateral breast cancer events. Currently, new therapeutic targets are under investigation, but the beneficial effect of prolonged treatment for high-risk patients, identified by using multigenomic tests, remains unclear. Thus, further studies need to be performed to confirm the advantage of extended adjuvant ET in selected patients.

Original languageEnglish
JournalTherapeutic Advances in Medical Oncology
Volume10
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Breast Neoplasms
Tamoxifen
Therapeutics
Recurrence
Aromatase Inhibitors
Estrogen Receptors
Disease-Free Survival
Biomarkers
Neoplasms

Keywords

  • aromatase inhibitor
  • breast cancer
  • gene-expression profiling
  • hormone receptor-positive breast cancer
  • hormone therapy
  • luminal breast cancer
  • molecular testing
  • tamoxifen

ASJC Scopus subject areas

  • Oncology

Cite this

@article{2fe46c21360b41bdbdcf159e55a0772d,
title = "Optimal management of luminal breast cancer: how much endocrine therapy is long enough?",
abstract = "Patients with early estrogen receptor-positive breast cancer are at continuous risk of relapse even after more than 10 years of follow up. Currently, no biomarker that identifies patients for early versus late recurrence, or one that selects patients or tumors for longer versus shorter durations of endocrine therapy (ET) is available and a crucial question is how to properly select patients who could be spared extended ET or those who require it. In the last 20 years more than 40,000 women were enrolled in randomized trials to answer the question of optimal duration of ET. According to the results of these studies extended adjuvant ET is more effective than standard 5 years of adjuvant ET. Extended ET in patients who remain premenopausal after 5 years of adjuvant tamoxifen is still tamoxifen for another 5 years. Extended ET with aromatase inhibitors (AIs) should be offered to postmenopausal women with substantial residual risk of relapse after completing 5 years of tamoxifen therapy. Extension of AI treatment to 10 years resulted in significantly better 5-year disease-free survival including disease recurrence local/distant or the occurrence of contralateral breast cancer events. Currently, new therapeutic targets are under investigation, but the beneficial effect of prolonged treatment for high-risk patients, identified by using multigenomic tests, remains unclear. Thus, further studies need to be performed to confirm the advantage of extended adjuvant ET in selected patients.",
keywords = "aromatase inhibitor, breast cancer, gene-expression profiling, hormone receptor-positive breast cancer, hormone therapy, luminal breast cancer, molecular testing, tamoxifen",
author = "Elisabetta Munzone and Marco Colleoni",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/1758835918777437",
language = "English",
volume = "10",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Optimal management of luminal breast cancer

T2 - how much endocrine therapy is long enough?

AU - Munzone, Elisabetta

AU - Colleoni, Marco

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Patients with early estrogen receptor-positive breast cancer are at continuous risk of relapse even after more than 10 years of follow up. Currently, no biomarker that identifies patients for early versus late recurrence, or one that selects patients or tumors for longer versus shorter durations of endocrine therapy (ET) is available and a crucial question is how to properly select patients who could be spared extended ET or those who require it. In the last 20 years more than 40,000 women were enrolled in randomized trials to answer the question of optimal duration of ET. According to the results of these studies extended adjuvant ET is more effective than standard 5 years of adjuvant ET. Extended ET in patients who remain premenopausal after 5 years of adjuvant tamoxifen is still tamoxifen for another 5 years. Extended ET with aromatase inhibitors (AIs) should be offered to postmenopausal women with substantial residual risk of relapse after completing 5 years of tamoxifen therapy. Extension of AI treatment to 10 years resulted in significantly better 5-year disease-free survival including disease recurrence local/distant or the occurrence of contralateral breast cancer events. Currently, new therapeutic targets are under investigation, but the beneficial effect of prolonged treatment for high-risk patients, identified by using multigenomic tests, remains unclear. Thus, further studies need to be performed to confirm the advantage of extended adjuvant ET in selected patients.

AB - Patients with early estrogen receptor-positive breast cancer are at continuous risk of relapse even after more than 10 years of follow up. Currently, no biomarker that identifies patients for early versus late recurrence, or one that selects patients or tumors for longer versus shorter durations of endocrine therapy (ET) is available and a crucial question is how to properly select patients who could be spared extended ET or those who require it. In the last 20 years more than 40,000 women were enrolled in randomized trials to answer the question of optimal duration of ET. According to the results of these studies extended adjuvant ET is more effective than standard 5 years of adjuvant ET. Extended ET in patients who remain premenopausal after 5 years of adjuvant tamoxifen is still tamoxifen for another 5 years. Extended ET with aromatase inhibitors (AIs) should be offered to postmenopausal women with substantial residual risk of relapse after completing 5 years of tamoxifen therapy. Extension of AI treatment to 10 years resulted in significantly better 5-year disease-free survival including disease recurrence local/distant or the occurrence of contralateral breast cancer events. Currently, new therapeutic targets are under investigation, but the beneficial effect of prolonged treatment for high-risk patients, identified by using multigenomic tests, remains unclear. Thus, further studies need to be performed to confirm the advantage of extended adjuvant ET in selected patients.

KW - aromatase inhibitor

KW - breast cancer

KW - gene-expression profiling

KW - hormone receptor-positive breast cancer

KW - hormone therapy

KW - luminal breast cancer

KW - molecular testing

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=85054793958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054793958&partnerID=8YFLogxK

U2 - 10.1177/1758835918777437

DO - 10.1177/1758835918777437

M3 - Review article

AN - SCOPUS:85054793958

VL - 10

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

ER -